SAN DIEGO--(BUSINESS WIRE)--Mar 7, 2007 - MultiCell Technologies, Inc. (OTCBB:MCET), developing first-in-class drugs based on advanced immune system modulation technologies, has completed a financing agreement with La Jolla Cove Investors (LJCI) for up to $13 million for the development of the Company’s lead therapeutics programs targeting multibillion dollar markets.
